Introduction: cardiovascular disease in type 2 diabetes – Where do we come from.

26 August 2017 (15:30 - 15:40)

Organised by:

Video

Sign in to view the resources

Slides

About the speaker

Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail

Cardiovascular effects of GLP-1 receptor agonists.

Doctor J. Plutzky (Boston, US)

Presentation thumbnail

Results from the LEADER cardiovascular outcomes trial.

Professor N. Poulter (London, GB)

Presentation thumbnail

Perspectives on results from recent CVOTs in type 2 diabetes.

Professor L. Ryden (Stockholm, SE)

Presentation thumbnail

Panel discussion - Improving CV outcomes in type 2 diabetes: A novel role for GLP-1 receptor agonists?

Professor L. Ryden (Stockholm, SE) Professor N. Poulter (London, GB) Doctor J. Plutzky (Boston, US)

Access the full session

Session thumbnail

Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?

The Event

ESC Congress 2017

26 August 2017 15:30 CET

You may be interested in

Webinar

EAPC Webinar: Type 2 Diabetes and cardiovascular risk

12 March 2019

Congress Presentation

To improve the quality of secondary prevention strategies in diabetic patients: the BRING-UP Prevention study results

5 April 2025

Congress Presentation

Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes

1 September 2025

Congress Presentation

Welcome & introduction.

28 August 2022

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources